Reanne Booker

@UVic PhD, clinical researcher, heme/onc (myeloma) & palliative care NP, mama. Vanier scholar. Former President of @CANO_ACIO
#QualityOfLife #GlobalOncology

[Reanne Booker @Rea_Booker]

Friday thoughts...

[Reanne Booker @Rea_Booker]

@VincentRK Wow!!! just that short clip was enough to get me smiling ear to ear and simultaneously, give me chills. What an incredible talent!! 🎶❤️

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Pictures worth 1000 words - excellent 🇩🇰 #MMsm work in @AjHematology!

ABCD study of prophylactic toci and analysis of primary IVIG PPx with BCMA bsAbs in myeloma.

Answer clear as day: both PPx toci and PPx IVIG are essential safety interventions 💪🏻 We need to work on ⬇️ cost!

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Hey everyone, want to catchup on the latest highlights from #ASCO26 ? I cover all plenary trials and other important studies.
My @ecancer highlights video is now up! Check it out.

https://t.co/PvTmTEG0Qv

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

The most important paper of #ASCO26 just dropped in Nature Med! Or any other @asco or @myESMO meetings to be honest. When you hear someone present “the toxicities were acceptable”, please respond “downplaying toxicities is not acceptable”. Thank you @NatureMedicine for publishing this piece.

https://t.co/ydAfoTWVJ0

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Time to highlight this video again in the context of #ASCO26 . Remember, truth is not a popularity contest and don’t outsource critical thinking!

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

Published today and presenting tomorrow! 📚➡️🎤

Excited to share our @ASCO Ed Book chapter on the contemporary challenges of EOC care @KimmieNgMD @drtarahenderson #IreneSu

Looking forward to tomorrow’s discussion at #ASCO26

https://t.co/geEMt1uKhR

[Reanne Booker @Rea_Booker]

@realbowtiedoc @PallOncCoP @ramsedhom @tomleblancMD @imdat_eroglu Wow!! Congrats @PallOncCoP!! Wonderful to see so many people come together for #PalliativeOncology!
I'm hoping to attend the @ASCO annual meeting next year and look forward to seeing you all in person!

#CancerCare
#PalliativeCare
#ASCO2026

[Vincent Rajkumar @VincentRK]

We have a fellowship @MayoClinic for cellular therapy! 👇

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Relevant for every ASCO meeting! #asco26

[Reanne Booker @Rea_Booker]

@BradenMannsYYC Yes!! In addition to significant anxiety caused by abnormal results that ultimately may not change patient outcomes, such abnormal results may impede someone's ability to get life insurance, critical illness insurance, travel insurance, etc.

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

One of the happiest moments of #asco26 ! Thanks @oncodaily !

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: MajesTEC-9 trial of teclistamab vs. PVd or Kd after 1-3 prior lines shows tec w/ better 18-mo. PFS (69.8% vs. 26.9%), OS (79.2% vs. 68.6%) but more G3/4 AEs (CRS 66.0%, ICANS 4.1%, G3/4 infxns 41.6% vs 29%) & more deaths: https://t.co/iCI40IWYKa. #mmsm

[Reanne Booker @Rea_Booker]

@oncology_bg @OncologyBGLab @oncodaily Amazing!! You are doing such incredible work to improve cancer care worldwide. Thanks to you and your colleagues for all you do!!

#CancerCare
#ASCO2026

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Now that new results have started to trickle in from #ASCO26, I’d like to remind you all to use this primer to evaluate these results. My most downloaded paper from @JCOOP_ASCO .

https://t.co/wm7VADipUS

[Craig's Cause Pancreatic Cancer Society @CraigsCauseCan]

PATIENTS & CAREGIVERS — WE NEED YOU!
We’re aiming for 500 surveys to:
1️⃣ Review real patient data
2️⃣ Advocate for better diagnosis, treatment, and management of pancreatic cancer

Your voice matters.
Take the survey. Help us change the outcomes. https://t.co/TTqmRHk3gL

[Reanne Booker @Rea_Booker]

@panagis21 @JHUPress Just ordered my copy (via https://t.co/V1Ve0USHa2)! I've been compiling a list of 'must reads' for the flight to/from Greece in July.
Can't wait to read it!

[Parksy @PfParks]

Getting towards the end of a long journey…

Come on out and let’s have a frank conversation!!

[Craig's Cause Pancreatic Cancer Society @CraigsCauseCan]

At diagnosis, investigation matters.
Exploring clinical trials early is critical—each standard treatment can limit future trial eligibility. Research shows clinical trial participants often have better outcomes and help advance new treatments.

Ask at diagnosis. Time matters.

[Parksy @PfParks]

Come on out Edmonton and Sherwood Park area.

Let’s talk about HC and have a meaningful discussion on a topic important to all Albertans.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

Pleasure working with @ASCO on this! Living guidelines in myeloma #MMsm reflect how rapidly the field is changing... this update ≤6 months after our last one!

CAR-T and bsAbs (tec-dara) now on equal footing for relapsed myeloma at first relapse - shared decision-making is 🔑